Modulating angiogenesis: More vs less

JAMA

Volumn 292, Issue 8, 2004, Pages 972-977

  Sivakumar, Branavan ^a,b   Harry, Lorraine E ^a   Paleolog, Ewa M ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOSTATIN; BEVACIZUMAB; CD51 ANTIGEN; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; INFLIXIMAB; IRINOTECAN; MEDI 552; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; SUNITINIB; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VATALANIB; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTHRITIS; BLOOD VESSEL; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG TARGETING; FRACTURE HEALING; GENE THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 4143094910     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.8.972     Document Type: Review

References (53)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Genetech Inc. FDA approves avastin, a targeted therapy for first-line metastatic colorectal cancer patients. Available at: http://www.gene.com/gene/ news /press-releases/display.do?method=detail &id=7167. Accessibility verified July 19, 2004.
3. Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res Part C Embryo Today. 2003;69:363-374.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
5. Lip PL, Blann AD, Hope-Ross M, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001;108:705-710.
6. Eskens FA. Angiogenesis inhibitors in clinical development. Br J Cancer. 2004;90:1-7.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
8. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003;100:7785-7790.
9. Posey JA, Ng TC, Yang B, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res. 2003;9:1323-1332.
10. Thomas AL, Morgan B, Drevs J, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol. 2003;30(3 suppl 6):32-38.
11. Emery P, Buch M. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. BMJ. 2002; 324:312-313.
12. Brenchley PE. Angiogenesis in inflammatory joint disease. Clin Exp Immunol. 2000;121:426-429.
13. Hirohata S, Sakakibara J. Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet. 1999;353:1331.
14. Rooney M, Condell D, Quinlan W, et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 1988;31:956-963.
15. Walsh DA, Wade M, Mapp PI, et al. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol. 1998;152:691-702.
16. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol. 2002; 17:961-972.
17. Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44:2055-2064.
18. Etherington PJ, Winlove P, Taylor P, et al. VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Clin Exp Rheumatol. 2002;20:799-805.
19. Peters CL, Morris CJ, Mapp PI, et al. The transcription factors hypoxia-inducible factor 1 alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004;50:291-296.
20. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol. 1999;115:176-182.
21. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNF-α and IL-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258-1265.
22. Williamson SC, Feldon P. Extensor tendon ruptures in rheumatoid arthritis. Hand Clin. 1995;11: 449-459.
23. Brown FE, Brown ML. Long-term results after tenosynovectomy to treat the rheumatoid hand. J Hand Surg Am. 1988;13:704-708.
24. Ertel AN. Flexor tendon ruptures in rheumatoid arthritis. Hand Clin. 1989;5:177-190.
25. Jain A, Nanchahal J, Troeberg L, et al. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum. 2001;44:1754-1760.
26. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther. 2003;10:1950-1960.
27. Lu J, Kasama T, Kobayashi K, et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol. 2000; 164:5922-5927.
28. Sone H, Kawakami Y, Sakauchi M, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun. 2001;281:562-568.
29. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.
30. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation. 2003;108: 2613-2618.
31. Lei Y, Haider HK, Shujia J, Sim ES. Therapeutic angiogenesis. Basic Res Cardiol. 2004;99:121-132.
32. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003; 107:1359-1365.
33. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;102:965-974.
34. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease. Circulation. 2003;108:1933-1938.
35. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001; 104:1046-1052.
36. Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361:47-49.
37. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep. 2001;3:225-233.
38. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429.
39. Celletti FL, Waugh JM, Amabile PG, et al. Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol. 2002;13:703-707.
40. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004;363:751-756.
41. Whiteside LA, Ogata K, Lesker P, Reynolds FC. The acute effects of periosteal stripping and medullary reaming on regional bone blood flow. Clin Orthop. 1978;131:266-272.
42. Carrington JL, Roberts AB, Flanders KC, et al. Accumulation, localization, and compartmentation of transforming growth factor beta during endochondral bone development. J Cell Biol. 1988;107:1969-1975.
43. Simmons DJ. Fracture healing perspectives. Clin Orthop. 1985;200:100-113.
44. Glowacki J. Angiogenesis in fracture repair. Clin Orthop. 1998;355(suppl):S82-S89.
45. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623-628.
46. Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development. 2002;129: 1893-1904.
47. Hausman MR, Schaffler MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone. 2001;29:560-564.
48. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A. 2002;99:9656-9661.
49. Street JT, Wang JH, Wu QD, et al. The angiogenic response to skeletal injury is preserved in the elderly. J Orthop Res. 2001;19:1057-1066.
50. Street J, Winter D, Wang JH, et al. Is human fracture hematoma inherently angiogenic? Clin Orthop. 2000;378:224-237.
51. Pufe T, Wildemann B, Petersen W, et al. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing. Cell Tissue Res. 2002;309:387-392.
52. Eckardt H, Bundgaard KG, Christensen KS, et al. Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF-inhibitor to the rabbit tibia during distraction osteogenesis. J Orthop Res. 2003; 21:335-340.
53. Hiltunen MO, Ruuskanen M, Huuskonen J, et al. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J. 2003;17:1147-1149.